

**PRESS RELEASE**  
**[UNDER EMBARGO UNTIL 8.00 AM ON 13.10.2023]**

**INTA, the first spin-off of the Scuola Normale Superiore and the CNR (National Research Council of Italy), closes a €2 million Seed round led by Eureka! Fund, in collaboration with LIFTT and Deep Ocean Capital.**

**Pisa, 13 October 2023 – INTA Systems (INTA)**, a startup that develops portable diagnostic products and the first joint spin-off of the Scuola Normale Superiore (University of Pisa) and the CNR (National Research Council of Italy), today announces the closing of a 2,000,000 Euro "Seed" investment round, led by "Eureka! Fund I - Technology Transfer," managed by EUREKA! Venture SGR, and participated in by Liftt and Deep Ocean Capital SGR through the "Deep Blue Ventures" fund.

INTA has operational sites in Pisa, at the NEST Laboratory (Nanoscience and Nanotechnology Research Center) and at the GATE - Galileo Aggregator for Technology & Enterprise. INTA develops and manufactures ultra-sensitive, portable lab-on-chip devices for rapid fluid analysis. The primary application area is in the biomedical field, but the technology, based on acoustic waves, can also be used in security, Industry 4.0, and food analysis. INTA's patented lab-on-a-chip devices can simultaneously detect a wide range of analytes (e.g., proteins, antibodies, nucleic acids, viruses, bacteria) in a few minutes in a simple and decentralized way. To achieve this, INTA integrates advanced knowledge of material physics, nanostructure fabrication processes, innovative biomolecule conjugation techniques, and data analysis using artificial intelligence algorithms.

Since its creation in 2020, INTA has achieved significant milestones, including the development and validation of its first prototype diagnostic system in the biomedical field, the NanoAnalyzer, the expansion of its patent portfolio with new patent applications, the conclusion of key industrial collaborations, and the near tripling of its workforce. The next challenge for the future is to develop and certify the first commercial product dedicated to the rapid and safe detection of brain injuries, eliminating false positives and using the subsequent standard investigation method (i.e., CT scans) only when necessary.

*"The results achieved by INTA through the 'pre-seed' investment have exceeded our expectations. Many of the challenges we set ourselves at the beginning of this fantastic journey have been overcome. However, new and even more exciting ones are emerging,"* said **Matteo Agostini**, CEO and Co-founder of INTA. *"The initial dream of bringing to market a technology that has an impact on both the economy and society is becoming a reality."*

*"In our investment evaluations, we emphasize the team's motivation to realize the potential of the technologies presented to us. From our first investment with A11 Venture, INTA has demonstrated a strong belief and the necessary skills and focus to prove the value they are creating and to engage other investors in this entrepreneurial journey,"* comments **Anna Amati**, Partner at Eureka! Fund. *"We look forward to continuing to grow with them and other investors who join us in this venture."*

*"The added value of INTA Systems lies in its ability to make biomedical diagnostics accessible through a portable device for rapid analysis of biological agents such as bacteria, viruses, antibodies, and proteins. Its first application allows for the diagnosis of brain injury by analyzing blood through six specific markers, helping to classify patients before they undergo CT scans and MRI scans. We believe that this technology has huge potential in the healthcare and in areas such as environmental monitoring and food analysis,"* says **Teresa De Nadai**, who led the investment for LIFTT.



*"We are delighted that INTA was the first investment of our fund, which completed its first closing in the spring of 2023," says **Domenico Nesci**, the Partner who led the investment for the Deep Blue Ventures fund. "The technology which comes from a leading research center in our country and is of paramount importance, together with the team and the market outlook, give us confidence in the company's ability to succeed in its growth journey. Furthermore, artificial intelligence and the healthcare sector are perfectly aligned with Deep Blue Ventures' investment thesis."*

\*\*\*

EUREKA! Venture SGR was advised by the law firm Hilex, with a team led by Partner Francesco Torelli and Senior Associate Serena Nasuti.

LIFTT and Deep Ocean Capital SGR were advised by the law firm Sani Zangrando, with a team led by lawyer Francesco Santoro and including lawyer Marianna Moscarelli and Mr. Marco Cardaci.

The company and its founders received legal assistance from the law firm of lawyer Lorenzo Carboni in Pisa.

\*\*\*

#### **INTA**

INTA Systems is the first spin-off of the National Research Council Nanoscience Institute of Pisa (CNR-NANO) and the Scuola Normale Superiore of Pisa (SNS). It operates from its headquarters at the NEST laboratory in Pisa, a research center for nanoscience and nanotechnology. The company develops and manufactures ultra-sensitive, portable lab-on-chip devices for rapid fluid analysis. Its main applications are in various fields, including biomedicine, security, Industry 4.0, and food analysis. INTA's patented lab-on-a-chip devices can quickly and easily detect a wide range of analytes, such as proteins, antibodies, nucleic acids, viruses, and bacteria, in a decentralized manner. INTA combines advanced knowledge of materials physics, nanostructure fabrication processes, innovative biomolecule conjugation techniques, and data analysis using artificial intelligence algorithms.

For further information, please visit [www.intasystems.net](http://www.intasystems.net)

#### **EUREKA! Venture SGR**

EUREKA! Venture SGR is an independent Venture Capital company, authorized by the Bank of Italy, focused on investments in Deep Tech, which includes investments in Deep Science and Digital Tech. The company manages approximately €110 million, including its first alternative investment fund, "Eureka! Fund I – Technology Transfer," launched in July 2020. The fund invests in proof-of-concept projects, spin-offs, startups, and enterprises aimed at commercializing the results of scientific research activities in Italy, particularly in the fields of advanced materials and materials science and engineering. EUREKA! Venture SGR also manages a second fund, the BlackSheep Fund, launched in August 2021, which targets digital technologies such as AI and big data applied to the MadTech (marketing and advertising) sector.

For further information, please visit [www.eurekaventure.it](http://www.eurekaventure.it)

#### **LIFTT**

LIFTT is a "not only for profit" investment holding company that offers an innovative and dynamic approach to venture capital applied to technology transfer. Chaired by entrepreneur and scientist Stefano Buono, LIFTT has 195 private and institutional investors, including Azimut, Fondazione Compagnia di San Paolo, and CRT, and has raised €103 million to date. Launched in 2020, LIFTT focuses on deep tech investments and has already invested in 42 innovative startups and SMEs across different market sectors.

For further information, please visit [www.liftt.com](http://www.liftt.com)

#### **Deep Ocean Capital SGR**

Deep Ocean Capital SGR operates in reserved alternative investment funds (FIA) dedicated to the private capital market. In the spring of 2023, SGR launched the first FIA fund, Deep Blue Ventures (DBV), and completed the first closing of the fund. DBV is a venture capital fund aimed at fostering the development of Italian innovation ecosystems in the field of deep tech, using science and technology to promote the growth of startups based on the results of academic, corporate, or industrial research. The fund is particularly interested in technology areas related to artificial intelligence in sectors such as space, health, and climate tech.

For further information, please visit [www.deepoceancapital.it](http://www.deepoceancapital.it)